Alleged violations of the Code during an event
If, as per your judgment, actions were taken during the conduct of a scientific event, with which the participation/sponsorship by a company that has signed the Code of Ethics of the Research-based Pharmaceutical Industry in Bulgaria raises doubts about a potential violation of the provisions of Article 10 of the Code, please report for them.
ESMO IN FOCUS: SARCOMA AND RARE CANCERS BULGARIA 2027
Last update:
21/09/26
Organized by:
The Bulgarian Scientific Society for Immuno-Oncology (BSIO)/ БЪЛГАРСКО НАУЧНО ДРУЖЕСТВО ПО ИМУНООНКОЛОГИЯ (БНДИО)
Place:
Intercontinental Hotel, Sofia
Start date:
10/04/27
End date:
10/04/27
App. Nr. of HCP:
80
Specialists:
Immuno-Oncology, varia
Any practice that might create confusion about the real scientific and educational purpose of scientific events sponsored by industry or to which industry sponsors HCPs should not be tolerated.
ARPharM Final Assessment:
12/03/27
Location and Venue
Hospitality Provided (Directly or Indirectly) to HCP
Information that would allow for a preliminary assessment is not yet available on the event website.
Other Activities
Information that would allow for a preliminary assessment is not yet available on the event website.
Accompanying Persons
Information that would allow for a preliminary assessment is not yet available on the event website.
Scientific Programme Schedule / Structure
Син - No scientific programme could be found on the event’s website.
Legend
ARPharM’s pre-assessment process is ongoing.
Based on information provided through one of the ways described above (on the date indicated), arrangements would not raise concern with regard to provisions of the ARPharM Article 10 Code of Ethics provisions.
Based on information provided through one of the ways described above (on the date indicated), arrangements may raise concern with regard to provisions of the ARPharM Article 10 Code of Ethics provisions.
It is always recommended to check the rules prevailing under applicable national codes.
EXHIBITIONS: please read carefully the provisions of the ARPharM HCP Code and the additional guidance.